文献速递头痛与眩晕

急性偏头痛试验中安慰剂反应的幅度与决定因素:系统综述与荟萃分析

Magnitude and Determinants of Placebo Response in Acute Migraine Trials: A Systematic Review and Meta-Analysis.
PubMed 文献 · Neurology · 2026-07-10

该研究系统检索并分析了1991至2025年间126项急性偏头痛治疗的随机对照试验,共纳入24,614名安慰剂组受试者。结果显示,安慰剂组2小时无痛率为11%(95%CI 10%-12%),且该反应随时间显著增加,并受给药途径、基线头痛严重程度及接受活性治疗概率等因素影响。

要点

  • 急性偏头痛试验中安慰剂组2小时无痛率为11%,预测区间为4%-27%。
  • 鼻内和皮下给药的安慰剂反应高于口服给药(14%和13% vs 10%)。
  • 安慰剂反应随时间显著增加,需在试验设计中予以考虑。

核心结论

  • 安慰剂反应在急性偏头痛随机对照试验中占比较大且呈逐年增加趋势。

研究设计与样本

  • 系统检索PubMed、Embase、Cochrane Central、ClinicalTrials.gov及欧洲和日本试验注册库至2025年11月,纳入126项双盲、平行组、2期或3期随机对照试验,共24,614名安慰剂组受试者。

主要发现

  • 安慰剂组2小时无痛率为11%(95%CI 10%-12%;预测区间4%-27%)。
  • 鼻内给药安慰剂2小时无痛率为14%(95%CI 12%-16%),皮下给药为13%(95%CI 8%-20%),均高于口服给药的10%(95%CI 9%-12%)(p < 0.05)。
  • 基线重度头痛患者比例较低与安慰剂反应较大相关(β -1.38;95%CI -2.37至-0.38;p < 0.01)。
  • 接受活性治疗概率较低与安慰剂反应较大相关(β -1.20;95%CI -2.02至-0.38;p < 0.005)。
  • 安慰剂反应随时间显著增加(β 0.03;95%CI 0.01-0.04;p < 0.001)。

临床怎么用

  • 解读急性偏头痛试验结果时需考虑安慰剂反应的背景,尤其是不同给药途径和患者特征的影响。
  • 试验设计应优化以维持检测灵敏度,并规范沟通和透明报告。

局限性

  • 探索性分析提示非白种人、亚洲国家及gepant试验中疼痛缓解的安慰剂反应较高,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Migraine is a highly prevalent and disabling neurologic disorder. Beyond drug-specific mechanisms, the role of contextual, individual-related, and disease-related factors remains poorly characterized. We quantified placebo response in randomized controlled trials (RCTs) of acute migraine treatments and identified patient-level, drug-level, and study-level determinants. METHODS: This meta-analytic review searched PubMed, Embase, Cochrane Central, ClinicalTrials.gov, and the European and Japanese Trial Registers from inception to November 2025 for published/unpublished, double-blind, parallel-group, phase 2 or 3 RCTs evaluating acute pharmacologic migraine treatments. Placebo rates with 95% CIs and prediction intervals (PIs) were pooled using random-effects models. Subgroup analyses and meta-regressions explored potential drivers. The primary outcome was 2-hour pain freedom after placebo administration. Secondary outcomes included 2-hour pain relief, sustained pain freedom, rescue medication use, global impression of improvement, and most bothersome symptom (MBS) freedom. RESULTS: We analyzed 126 RCTs published between 1991 and 2025, comprising 24,614 placebo-treated participants (mean age range, 34.8-45.2 years; female, 65.2%-96.9%). The pooled 2-hour pain freedom rate was 11% (95% CI 10%-12%; PI: 4%-27%). The highest estimates were observed for intranasal (14%; 95% CI 12%-16%) and subcutaneous (13%; 95% CI 8%-20%) administration, compared with oral (10%; 95% CI 9%-12%) (p < 0.05). A lower proportion of patients with severe baseline headache and a lower probability of receiving an active treatment were associated with greater responsiveness (β -1.38; 95% CI -2.37 to -0.38; p < 0.01 and β -1.20; 95% CI -2.02 to -0.38; p < 0.005, respectively). Placebo response increased significantly over time (β 0.03; 95% CI 0.01-0.04; p < 0.001), even after multivariable adjustment. Placebo rates were 34% for 2-hour pain relief, 9% for sustained pain freedom, 52% for rescue medication use, 24% for positive global impression, and 34% for MBS freedom. Exploratory analyses of pain relief showed high placebo responses among non-Caucasian individuals, in Asian countries, and in gepant RCTs. DISCUSSION: Placebo response represents a substantial and increasing component of outcomes in acute migraine RCTs. Improved trial design, standardized communication, and transparent reporting may enhance effect-size interpretation and preserve assay sensitivity in future trials.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Makita LM, Katsuyama E, Christensen RH, et al. Magnitude and Determinants of Placebo Response in Acute Migraine Trials: A Systematic Review and Meta-Analysis. Neurology. 2026. PMID: 42430679. doi:10.1212/WNL.0000000000218213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。